ImmunoGenix

Executive Summary

ImmunoGenix is a preclinical-stage biotechnology company headquartered in San Diego, California, pioneering the discovery and development of next-generation antibody-based immunotherapies. Founded in 2018, the company leverages a proprietary synthetic biology platform to generate fully human, multi-specific antibodies with optimized properties for efficacy, stability, and manufacturability. By addressing key challenges in antibody engineering, ImmunoGenix aims to create novel treatments for oncology and autoimmune diseases, two of the largest therapeutic areas with significant unmet medical needs. The platform has the potential to unlock new target combinations and improve patient outcomes through enhanced specificity and reduced side effects.

Upcoming Catalysts (preview)

• Q2 2027Lead Candidate IND Filing80% success
• Q1 2027Major Pharmaceutical Partnership or Licensing Deal50% success
• Q4 2026Series D or Oversubscribed Funding Round70% success